Information Provided By:
Fly News Breaks for September 15, 2016
SPHS
Sep 15, 2016 | 08:24 EDT
Roth Capital analyst Joseph Pantginis started Sophiris Bio with a Buy and $8 price target. The analyst believes the company's lead asset, PRX302, has the potential to address the large markets of benign prostate hyperplasia with a positive Phase 3 in hand and localized prostate cancer.
News For SPHS From the Last 2 Days
There are no results for your query SPHS